Overview

Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to test whether the addition of the drug plerixafor to treatment with chemotherapy and G-CSF can better activate your bone marrow stem cells to improve the chances of transplant. The study will look for the activation of a certain type of blood cell, called CD34+ cells in patients who receive plerixafor, chemotherapy and G-CSF. The investigators will follow the number of patients that achieve the target numbers of CD34+ cells. The number of patients achieving the target level of CD34+ cells, and the total number of CD34+ cells, will be compared to the numbers in previous studies testing just chemotherapy and G-CSF, without plerixafor. The investigators will also test the safety of the combination of plerixafor with chemotherapy and G-CSF and look at the success of the transplantation after 12 months.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Emory University

Collaborator:

Genzyme, a Sanofi Company

Treatments:

JM 3100
Plerixafor

Criteria

Inclusion Criteria:

1. Age 18-70 years

2. Multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) patients in first or second
complete or partial remission

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

4. Up to 3 prior treatment regimens

5. Meet all eligibility requirements for autologous transplant

6. Adequate marrow function defined as white blood cells (WBC) >3,000; ANC >1,500/mm3;
platelets >75,000/mm3

7. Adequate renal function defined as creatinine clearance > 30 mL/min by Cockcroft-Gault

8. Adequate liver function defined as aspartate aminotransferase (AST)/alanine
aminotransferase (ALT)/bilirubin < 2 times upper limit of normal

9. Able to provide informed consent

10. Women not pregnant and agree to use contraception

Exclusion Criteria:

1. High risk co-morbidities for acute treatment complications (e.g., symptomatic coronary
artery disease)

2. Brain metastases or carcinomatous meningitis

3. Previous treatment with high dose chemotherapy and autologous transplant

4. Previous attempt to collect B-hematopoietic progenitor cells (HPCs) following
mobilization with growth factors alone, growth factors and chemotherapy, or plerixafor
and growth factors

5. Acute infection or unexplained fever >38°C

6. Weight > 175% of ideal body weight as defined by the Devine equation

7. Experimental therapy within 4 weeks

8. Cytokine administration in the previous 14 days